Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 7/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.35 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | EDNRB | P24530 | 1/20 | 0.33 |
| ▸ | EDNRA | P25101 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14808551 | 0.86 | CA2 (0.44) | VEGFACA2CA5ACA1EPAS1 | |
| SCHEMBL31396119 | 0.83 | CA2 (0.40) | VEGFACA2CA1EPAS1SLC10A2 | |
| SCHEMBL12179248 | 0.79 | CA2 (0.38) | VEGFACA2CA5ACA1SLC10A2 | |
| SCHEMBL22438912 | 0.79 | KDM1A (0.39) | CA2CA1CA12CA4CA7 | |
| SCHEMBL31396203 | 0.76 | CA2 (0.39) | VEGFACA2CA5ACA1CA12 | |
| SCHEMBL7431183 | 0.74 | FFAR1 (0.39) | CA2CA1EDNRBEDNRA | |
| SCHEMBL10858571 | 0.73 | SLC6A2 (0.38) | VEGFACA2CA5ASLC10A2 | |
| SCHEMBL22439483 | 0.70 | TGM2 (0.40) | — | |
| SCHEMBL7124229 | 0.70 | DDB1 (0.37) | VEGFACA2CA1SLC10A2CA12 | |
| SCHEMBL29134300 | 0.70 | CA1 (0.35) | CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916593-B2 | Alkoxy-substituted 2-aminopyridines as ALK inhibitors | PFIZER INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916593-B2 | Alkoxy-substituted 2-aminopyridines as ALK inhibitors | PFIZER INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916593-B2 | Alkoxy-substituted 2-aminopyridines as ALK inhibitors | PFIZER INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-20130196952-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130196952-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130196952-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2013-08-01 | — | — | US | disclosed |
| EP-2566858-A2 | HETEROCYCLIC DERIVATIVES AS ALK INHIBITORS | Pfizer Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011138751-A2 | HETEROCYCLIC DERIVATIVES AS ALK INHIBITORS | PFIZER INC. (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196952-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | ALK, ETV6, ACVR1 | VEGFA 824/4885CA2 4120/4885CA5A 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.